

Based on the `Stock Detailed Analysis Report` for **TORNTPHARM.NS** (Torrent Pharmaceuticals Ltd.), here is the positional trading analysis.

### ### Step 1: Audit the Data

- \* **Data Present:**
  - \* Daily Price Charts (3-Year history).
  - \* Moving Averages (EMA 20, 50, 200) and crossover status.
  - \* Momentum Indicators (RSI, MACD, Bollinger Bands, Supertrend).
  - \* Fundamental Analysis (Revenue, Net Income, ROE, EPS growth).
  - \* Relative Strength (RS) analysis against the Pharma sector.
  - \* Analyst Estimates and Price Targets (Trendlyne data).
- \* **Data Missing:**
  - \* **Intraday Volume Profile:** While daily volume is present, specific volume-at-price data is missing to identify hidden supply/demand zones.
  - \* **Real-time Volume Confirmation:** The report indicates current volume (57,479) is significantly below the 20-day average (148,179) for the reporting day, which obscures the strength of the current breakout.
  - \* **Confidence Level:** **High**. The report provides a comprehensive technical and fundamental view. \*Note: The report date is simulated as 2026-01-03; the analysis treats this as the current effective date.\*

### ### Step 2: Analyze the Setup

- \* **Price Structure & Trend:** The stock is in a robust **Strong Uptrend**. Price is trading above all key EMAs (20 > 50 > 200), and the "Golden Cross" (EMA 50 crossing EMA 200) occurred significantly in the past (Jan 2024), confirming a mature bull market.
- \* **Momentum & Indicators:**
  - \* **MACD:** **Bullish** crossover with strengthening momentum (Page 12).
  - \* **RSI:** Currently at 67.90. This is bullish but approaching the "Overbought" threshold (70), suggesting limited immediate upside before a pause.
  - \* **Bollinger Bands:** The price (3885) is currently trading **above the Upper Bollinger Band** (3874). This indicates the stock is statistically overextended in the short term (%B = 1.08).
  - \* **Confluence:** The Supertrend is positive (Buy signal identified Nov 2025). However, the "Relative Strength" classification is **"Weakening Leader"** (Page 4), and the volume on the current candle is low relative to the average. This divergence (Price High, Volume Low, Band Breach) suggests exhaustion risk.

### ### Step 3: Formulate the Recommendation

**Decision: NO.**

#### **Why Invalid Now?**

While the long-term trend is bullish, entering a positional trade when the price is **above the Upper Bollinger Band** on **low volume** is high-risk. This typically results in a "mean reversion" pullback to the 20-day moving average or a consolidation period. The stock is technically expensive (Valuation Score 28.0) and chasing an overextended breakout reduces the probability of hitting the 15% upside target within the desired timeframe.

#### **Conditional Plan (Buy the Dip Strategy):**

Wait for the price to normalize and test support levels. The trend is up, so we look to buy on weakness, not strength.

- \* **Condition to Buy:** Price must retrace and demonstrate support near the **EMA 20** or the **Bollinger Band Middle Band (SMA 20)**. Alternatively, look for a consolidation box to form between 3800-3900 and buy on a high-volume breakout above 3900.
- \* **Entry Price:** **INR 3805 - INR 3820** (Zone of the 20-day SMA and EMA support).

\* **Stop Loss**: **INR 3675** (Close basis).

\* **Rationale**: This is just below the current Supertrend support level (3689) and allows breathing room below the EMA 50 (3749).

\* **Take Profit**: **INR 4150 - INR 4200**

\* **Rationale**: This targets a ~10% move from the entry zone, pushing into "Blue Sky" territory beyond the current analyst consensus of ~4024.

## # News & Analyst Targets

### \*\*\* Torrent Pharmaceuticals (TORNTPHARM) - Stock Research Report\*\*

**Date**: January 3, 2026

**Subject**: Weekly Update & Analyst Sentiment Analysis

---

### \*\*\* 1) Latest News for TORNTPHARM (This Week)\*\*

The following developments have occurred in the first week of January 2026:

#### \* **Credit Rating Affirmation (Jan 2, 2026)**:

**India Ratings and Research** has affirmed Torrent Pharma's Long-Term Issuer Rating at **IND AA+** with a **Stable** outlook. The agency also assigned a top-tier short-term rating of **IND A1+** to the company's proposed commercial paper program. This signals strong confidence in the company's credit profile and financial health.

#### \* **All-Time High Stock Performance (Jan 2, 2026)**:

The stock hit a fresh **all-time high** on Friday, January 2, 2026, gaining approximately 1% in a single session and outperforming the broader Sensex. The stock has shown resilience, gaining for four consecutive days.

#### \* **Upcoming Board Meeting (Scheduled Jan 5, 2026)**:

The company has a board meeting scheduled for **Monday, January 5, 2026**. The agenda includes the consideration of issuing Non-Convertible Debentures (NCDs) on a private placement basis, which is a key event for investors watching the company's capital raising activities.

### \*\*\* 2) Brokerage Upgrades & Downgrades\*\*

Recent analyst activity (Late Q4 2025 to Present) highlights a shift in sentiment:

\* **MarketsMojo (Upgrade)**: Upgraded the stock to **"Buy"** from "Hold" on **December 23, 2025**, citing improved technical momentum and strong financial indicators.

\* **BofA Securities (Upgrade)**: In November 2025, BofA upgraded the stock from "Neutral" to **"Buy"**, raising their price target significantly (see table below). They cited the J.B. Chemicals deal as a major long-term catalyst.

\* **Prabhudas Lilladher (Maintain)**: Maintained an **"Accumulate"** rating in their recent reports, highlighting steady growth in the domestic market and the strategic value of recent acquisitions.

### \*\*\* 3) Indirect & Strategic News Impacting TORNTPHARM\*\*

#### \* **Strategic Acquisition of J.B. Chemicals & Pharmaceuticals**:

This remains the single biggest driver of sentiment. The deal, valued at over INR 25,000 crore, is progressing through regulatory approvals (including recent CCI clearance). It is expected to make Torrent the 5th largest player in the Indian pharma market and add a lucrative Contract Development and Manufacturing Organization (CDMO) vertical to its portfolio.

#### \* **Sector Consolidation**:

The Indian pharmaceutical sector is witnessing a wave of M&A activity. Torrent's aggressive expansion is seen as part of a larger trend where top players are consolidating to build scale in chronic therapies and biosimilars.

#### \* **Strong Q2 FY26 Earnings Carryover**:

The market is still reacting positively to the strong Q2 FY26 results reported in November, where the company posted ~14% revenue growth and a ~30% jump in Net Profit, driven by robust performance in India, Brazil, and the US.

### \*\*4) Analyst Price Targets & Recommendations\*\*

Brokerage / Firm	Rating / Action	Price Target (INR)	Date of Report	Key Rationale
---	---	---	---	---
Prabhudas Lilladher	Accumulate	4,200	Nov 11, 2025	Strong domestic growth; J.B. Chemicals deal adds high-margin portfolio.
BofA Securities	Buy (Upgrade)	4,000	Nov 10, 2025	Upgrade driven by strong Q2 results and long-term synergies from acquisitions.
JP Morgan	Overweight	3,800	Mid-2025	India business expected to be a major growth engine; target raised from INR 3,650.
Trendlyne Consensus	Buy / Hold	3,880	Jan 02, 2026	Average of 14 analyst reports; represents a consensus view near current levels.
TradingView Consensus	Buy	4,045	Jan 02, 2026	<b>Bullish</b> average target with a high-end estimate of INR 4,500.

\*\*\*Disclaimer:\*\* This report is for informational purposes only and does not constitute financial advice. Please consult with a certified financial advisor before making any investment decisions.\*


# Stock Detailed Analysis Report

## **TORNTPHARM.NS**

Current Price: ₹3885.30

Generated: 2026-01-03 12:45

# TORNTPHARM.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	7.15%	10.36%
Net Income	Yes	No	15.39%	34.98%
ROE	Yes	No	4.22%	24.48%
EPS	Yes	No	15.39%	34.98%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.77%	3.55%
Net Income	Yes	7.85%	6.98%
ROE	Yes	6.57%	7.65%
EPS	Yes	7.78%	6.01%

# TORNTPHARM.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Weakening Leader</b>
RS Score:	53.4/100
:	

## == RS RATIOS ==:

1M RS:	<b>1.029 [Leader]</b>
3M RS:	<b>1.037 [Leader]</b>
6M RS:	<b>1.116 [Leader]</b>
1Y RS:	<b>1.133 [Leader]</b>
:	

## == TURNAROUND ANALYSIS ==:


Turnaround Status:	<b>Not Detected</b>
:	

## SIGNAL CRITERIA::


× Emerging RS:	<b>Not accelerating</b>
× Medium-term Lagging:	<b>Not lagging</b>
× Performance Improving:	<b>Not improving</b>

Relative Strength Analysis: TORNTPHARM.NS vs ^CNXPHARMA  
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline





## TORNTPHARM.NS - EMA Crossover Summary

EMA 20:	3809.04
EMA 50:	3749.47
EMA 200:	3532.87
Trend Status:	<b>Strong Uptrend</b>
Golden Cross Date:	2024-01-12 00:00:00
Golden Cross Price:	2468.75


TORNTPHARM.NS EMA Crossover Analysis



## TORNTPHARM.NS - Bollinger Bands Summary

<b>Current Price:</b>	3885.30
<b>Upper Band:</b>	3874.03
<b>Middle Band (SMA 20):</b>	3805.40
<b>Lower Band:</b>	3736.76
<b>%B:</b>	1.0821
<b>Band Width:</b>	0.0361
<b>Status:</b>	Above Upper Band
<b>Signal:</b>	None


TORNTPHARM.NS Bollinger Bands (20, 2) Analysis



## TORNTPHARM.NS - Supertrend Summary

Status:	<b>UPTREND (Buy)</b>
Supertrend Value:	3689.92
Signal Identified On:	2025-11-10

Supertrend Analysis for TORNTPHARM.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## TORNTPHARM.NS - MACD Summary

MACD Line:	31.24
Signal Line:	27.60
Histogram:	3.64
Trend:	<b>Bullish</b>
Momentum:	<b>Strengthening</b>
Signal:	None

TORNTPHARM.NS Price



TORNTPHARM.NS MACD (12, 26, 9)








# TORNTPHARM.NS - Volatility Squeeze Summary

BB Width:	0.0361
ATR:	55.3928
Total Signals:	40
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-29 00:00:00 (Price: 379.00)
Signal 2:	BB Squeeze + ATR Contraction at 2025-12-30 00:00:00 (Price: 382.00)
Signal 3:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00 (Price: 385.00)
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00 (Price: 388.00)
Signal 5:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00 (Price: 385.00)


# TORNTPHARM.NS - Volatility Squeeze Analysis




## TORNTPHARM.NS - RSI-Volume Summary

<b>Current RSI:</b>	67.90
<b>Current Volume:</b>	57479
<b>Volume MA 20:</b>	148179
<b>Bullish Divergences:</b>	2
<b>Bearish Divergences:</b>	1
<b>Bullish Div 1:</b>	Date: 2024-11-19 00:00:00, Price: 3094.85
<b>Bullish Div 2:</b>	Date: 2025-02-14 00:00:00, Price: 3013.85
<b>Bearish Div 1:</b>	Date: 2025-04-28 00:00:00, Price: 3335.00

# TORNTPHARM.NS RSI-Volume Divergence Analysis



## Trendlyne Snapshot - TORNTPHARM\_main



Trendlyne Snapshot - TORNTPHARM\_forecaster

